Shares surged +11.8% to $9.65 after Alpha Cognition reported second-quarter revenue of $6.09 million, crushing the $4.32 million Wall Street consensus by 41%. The beat signals that the company's Alzheimer's pill — the first new oral treatment in the category approved in over 15 years — is gaining traction far faster than the Street modeled. But the stock remains a micro-cap bet on a single drug with steep losses still mounting.
Sales Nearly Doubled Quarter-Over-Quarter, Proving the Drug Is Catching On
Q1 revenue was $3.5 million, itself representing 40% sequential growth over Q4 2025. Q2's $6.09 million effectively marks a 74% jump from Q1, suggesting prescriber adoption is accelerating sharply. As of Q1, about 75% of prescribers and 81% of facilities showed repeat use — a sign doctors are sticking with the medication. That repeat behavior is the single most important commercial metric for a drug this early in its launch.
Losses Are Still Deep, and the Cash Runway Has a Ticking Clock Adjusted EPS of -$0.40 barely missed the -$0.39 estimate, meaning the company is still spending far more than it earns. Operating expenses climbed to $11.6 million in Q1, reflecting heavy investment in commercial infrastructure.
Cash stood at $54.2 million at the end of Q1 , but with roughly $12 million in quarterly cash burn, the company has about a year of runway before it needs to raise more money — likely by selling new shares, which would dilute existing investors. Management targets operating profitability by 2027.
Wall Street Sees Massive Upside — If Execution Continues
Raymond James initiated coverage in July with an Outperform rating and a $20 price target, while the four-analyst consensus sits at a $16 average — roughly 66% above the current price. Analysts had projected full-year 2026 revenues of $22.3 million, a 106% improvement over the prior twelve months. If Q2's blowout pace holds, that target is within reach, but any stumble in insurance coverage expansion or prescriber growth could stall momentum quickly in a stock this small and volatile. The stock's beta is 2.61 , meaning it tends to swing more than two-and-a-half times as much as the broader market — a reminder that the ride from here will be anything but smooth.